NYXH
$3.12
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
Recent News
KORU Medical Systems, Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +50.00% and +0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
How The Nyxoah (ENXTBR:NYXH) Story Is Shifting As Assumptions And Risks Are Reworked
Nyxoah’s fair value estimate has been trimmed from €10.00 to €9.50, a €0.50 move that narrows the implied upside in the latest research. Analysts link this change to an updated set of assumptions and are debating what the revised target means for upside potential and execution risk. Read on to see how you can track these shifts and put the evolving Nyxoah story into context. Stay updated as the Fair Value for Nyxoah shifts by adding it to your watchlist or portfolio. Alternatively, explore...
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System
Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.
Why The Narrative Around Nyxoah Is Shifting Amid Fresh Developments and Analyst Caution
Nyxoah’s stock narrative is shifting as the consensus analyst price target has decreased from $12.30 to $10.00, reflecting a more conservative outlook in light of ongoing U.S. expansion efforts. This adjustment largely reflects analysts’ responses to recent developments, with optimism over product launch traction balanced by concerns regarding regulatory and reimbursement challenges. Stay tuned to discover how you can stay ahead of future changes in Nyxoah’s evolving story. Stay updated as...
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Health care stocks were edging higher premarket Wednesday, with the Health Care Select Sector SPDR F